UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
alendronic acid (611) 611
bisphosphonates (563) 563
science & technology (504) 504
life sciences & biomedicine (423) 423
osteoporosis (372) 372
humans (278) 278
female (246) 246
alendronate (196) 196
fractures (179) 179
endocrinology & metabolism (165) 165
animals (142) 142
medicine & public health (138) 138
bone mineral density (133) 133
aged (128) 128
bone density conservation agents - therapeutic use (124) 124
alendronate - therapeutic use (119) 119
male (112) 112
orthopedics (112) 112
alendronate - pharmacology (109) 109
middle aged (109) 109
patients (99) 99
biocompatibility (97) 97
post-menopause (96) 96
bone density (95) 95
biomedical materials (93) 93
bones (93) 93
risedronic acid (93) 93
femur (92) 92
hip (87) 87
rheumatology (87) 87
zoledronic acid (86) 86
osteoporosis - drug therapy (85) 85
bone density - drug effects (84) 84
bone (82) 82
osteoporosis, postmenopausal - drug therapy (81) 81
drug therapy (80) 80
endocrinology (78) 78
risk factors (78) 78
bone resorption (76) 76
parathyroid hormone (76) 76
analysis (75) 75
vertebrae (73) 73
alendronate - administration & dosage (72) 72
spine (72) 72
pharmacology & pharmacy (69) 69
research (69) 69
osteogenesis (68) 68
bone growth (67) 67
bone density conservation agents - administration & dosage (66) 66
drugs (66) 66
clinical trials (65) 65
diphosphonates - therapeutic use (65) 65
bone density conservation agents - pharmacology (64) 64
bone turnover (63) 63
calcium (62) 62
rats (60) 60
ovariectomy (59) 59
aged, 80 and over (57) 57
bisphosphonate (55) 55
dentistry (55) 55
bone density conservation agents - adverse effects (53) 53
care and treatment (53) 53
health aspects (53) 53
science & technology - other topics (53) 53
studies (53) 53
osteonecrosis (52) 52
mice (50) 50
multidisciplinary sciences (49) 49
osteoclasts (49) 49
menopause (48) 48
pharmacology/toxicology (48) 48
rodents (48) 48
density (47) 47
medicine (47) 47
bone loss (46) 46
technology (46) 46
collagen (45) 45
computed tomography (45) 45
postmenopausal women (45) 45
surgery (45) 45
health risk assessment (44) 44
jaw (44) 44
research article (44) 44
vitamin d (44) 44
alendronic-acid, adverse reactions (42) 42
estrogen receptors (42) 42
sodium (42) 42
alendronate - adverse effects (41) 41
dentistry, oral surgery & medicine (41) 41
metabolism (41) 41
phosphonates (41) 41
ibandronic acid (40) 40
raloxifene (40) 40
bone mass (39) 39
complications and side effects (39) 39
diphosphonates - administration & dosage (39) 39
science (39) 39
diphosphonates - adverse effects (38) 38
dosage and administration (38) 38
drug administration schedule (38) 38
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (734) 734
Chinese (10) 10
Japanese (3) 3
Russian (3) 3
French (2) 2
Dutch (1) 1
German (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of cellular and molecular medicine, ISSN 1582-1838, 12/2018, Volume 22, Issue 12, pp. 6122 - 6133
...). Additionally, fluvastatin reduced soluble ST2 secretion from HACM. IL‐33 was also up‐regulated by the general inhibitor of prenylation perillic acid, a RhoA kinase inhibitor Y... 
cardiac cells | interleukin‐33 | bisphosphonates | pleiotropic | statins | interleukin-33 | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Cell Biology | Research & Experimental Medicine | Lovastatin - pharmacology | Apoptosis - drug effects | Humans | Simvastatin - pharmacology | Fluvastatin - pharmacology | Monoterpenes - pharmacology | Heart Diseases - diet therapy | Myocardium - metabolism | Thiazolidines - pharmacology | Cytokines - genetics | Amides - pharmacology | Mevalonic Acid - pharmacology | Pravastatin - pharmacology | Myocardium - pathology | rhoA GTP-Binding Protein | Gene Expression Regulation - drug effects | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Interleukin-33 - genetics | Myocytes, Cardiac - drug effects | Fibroblasts - drug effects | 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid - pharmacology | Cyclohexenes - pharmacology | Heart - drug effects | Myocytes, Cardiac - metabolism | Heart Diseases - drug therapy | Pyridines - pharmacology | Diphosphonates - pharmacology | Interleukins | Statins | Cardiovascular agents | Heart | Interleukin | Lovastatin | mRNA | Myocytes | Pravastatin | Kinases | Bisphosphonates | Proteins | Lipophilic | Alendronic acid | Mevalonic acid | Fluvastatin | Fibroblasts | Cytokines | Simvastatin | RhoA protein | Cardiomyocytes | Ibandronic acid | Patients | Inhibitors | latrunculin B | Atorvastatin | Reductase | Index Medicus | Original
Journal Article
Osteoporosis international, ISSN 1433-2965, 11/2011, Volume 23, Issue 7, pp. 2043 - 2051
Journal Article
Journal Article
The Journal of biological chemistry, ISSN 1083-351X, 09/2001, Volume 276, Issue 36, pp. 33930 - 33937
Journal Article
Osteoporosis international, ISSN 0937-941X, 2/2012, Volume 23, Issue 2, pp. 625 - 633
...) dose of zoledronic acid with a once-weekly oral dose of alendronate with respect to markers of bone turnover in approximately 600 postmenopausal women... 
Osteoporosis | Medicine & Public Health | Orthopedics | Gynecology | Rheumatology | Zoledronic acid | Bone loss | Bisphosphonates | Bone markers | Endocrinology | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Collagen Type I - blood | Peptides - blood | Injections, Intravenous | Humans | Middle Aged | Imidazoles - administration & dosage | Osteoporosis, Postmenopausal - metabolism | Alendronate - therapeutic use | Bone and Bones - metabolism | Peptide Fragments - blood | Aged, 80 and over | Diphosphonates - therapeutic use | Female | Imidazoles - therapeutic use | Diphosphonates - adverse effects | Bone Density Conservation Agents - adverse effects | Administration, Oral | Imidazoles - adverse effects | Bone Density Conservation Agents - therapeutic use | Diphosphonates - administration & dosage | Procollagen - blood | Biomarkers - blood | Bone Density Conservation Agents - administration & dosage | Osteoporosis, Postmenopausal - drug therapy | Alendronate - adverse effects | Bone Density - drug effects | Osteoporosis, Postmenopausal - physiopathology | Aged | Alendronate - administration & dosage | Alendronate | Physiological aspects | Bones | Postmenopausal women | Research | Health aspects | Density | Clinical trials | Biomarkers | Drug therapy | Menopause | Index Medicus | Alendronic acid | Collagen (type I) | Bone mass | Intravenous administration | procollagen | Bone turnover | Post-menopause
Journal Article